Exploring the management of recurrent angioedema caused by different mechanisms

Curr Opin Allergy Clin Immunol. 2025 Feb 1;25(1):47-57. doi: 10.1097/ACI.0000000000001047. Epub 2024 Nov 28.

Abstract

Purpose of review: We aim to explore the most recent insights into the pathogenesis of recurrent angioedema caused by different mechanisms and then focus on the management and treatment approaches available.

Recent findings: The recently developed DANCE consensus classification identifies five types of angioedema: mast cell-mediated (AE-MC), bradykinin-mediated, because of intrinsic vascular endothelium dysfunction (AE-VE), drug-induced (AE-DI), and due to unknown mechanisms (AE-UNK). These subtypes require different management with treatment choices targeting the main pathogenetic pathways involved in each form. For AE-MC and AE-BK, the therapeutic landscape has been significantly widened in recent years. Conversely, there is a lack of consensus for the hereditary forms because of newly discovered mutations ( factor 12 , plasminogen, kininogen-1 , myoferlin, angiopoietin-1 , heparan sulfate 3-O-sulfotransferase 6 ) and AE-UNK.

Summary: Recurrent angioedema can present with or without wheals. Angioedema without wheals may be driven by bradykinin and/or mast cell mediators. The different forms respond to specific drugs and require a different management. For its potentially life-threatening and disfiguring features, angioedema should be promptly recognized and effectively treated. For this reason, enhancing awareness about various angioedema subtypes and their management provide a useful tool for the clinical practice.

Publication types

  • Review

MeSH terms

  • Angioedema* / diagnosis
  • Angioedema* / etiology
  • Angioedema* / therapy
  • Bradykinin* / metabolism
  • Endothelium, Vascular / immunology
  • Humans
  • Mast Cells* / immunology
  • Recurrence*

Substances

  • Bradykinin